Jeffrey S. Weber, MD, PhD: This has been extremely informative. But before we end this discussion, I’d like to get some final thoughts from each of the panelists. Dr Jason Luke?
Video Reports
The Role of BRAF Mutations in Melanoma
My name is Adil Daud. I’m a medical oncologist. I work at the University of California, San Francisco, where I direct melanoma research and the melanoma program.
Management of Patients with BRAF-Mutated Melanoma
My personal approach to sequencing treatments in BRAF-mutant patients is to look at all the different factors that are involved.
Melanoma: Progression After Immunotherapy
Jeffrey S. Weber, MD, PhD: Let’s transition to the elephant in the room. We’ve heard great things about single-agent PD-1 [programmed cell death protein 1] blockade, ipilimumab-nivolumab, BRAF/MEK—multiple combinations, all frontline therapy.